FAS and glioma: Accordingly, a CD95 decoy receptor blocking both the apoptotic and non-apoptotic signaling pathways, Asunercept (APG101), has nevertheless entered clinical trials for glioma and myelodysplastic syndrome (Wick et al., 2014; Boch et al., 2018).